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ps recently as 5 years ago, The New York Times reported
hat “the use of such drugs known as calcium channel
lockers is leading to nearly 85 000 unnecessary heart at-
acks and cases of congestive heart failure each year world-
ide.”1 This statement was based on a meta-analysis pur-
orting to show that calcium antagonists, when compared
ith conventional drugs, increase the risk of myocardial
nfarction and congestive heart failure.2 In contrast, the
LLHAT3 study documented that the occurrence of coro-
ary artery disease was virtually identical in the calcium
ntagonist, angiotensin-converting enzyme (ACE) inhibitor,
nd diuretic arm. Ironically, the meta-analysis in which the
rincipal investigator of ALLHAT participated was pub-
ished 5 years after the initiation of the ALLHAT study at
time when there was not a shred of evidence showing
hat calcium antagonists were harmful. The subsequent
ALUE4 study showed a better reduction of coronary artery
isease in the amlodipine arm than in the valsartan arm,
ossibly because there was a difference in blood pressure
avoring amlodipine. This, in a nutshell, set the stage for the
CTION study.5
ACTION was initiated in 1995, at the height of the
alcium antagonist controversy.6,7 At that time, short-acting
ormulations of nifedipine were considered harmful,8 and
here was no outcome evidence of long-acting calcium an-
agonist in coronary artery disease. ACTION clearly at-
ested to the safety of calcium antagonists in such patients.
here was no difference in all-cause death, cardiovascular
eath, noncardiovascular death, stroke, and myocardial in-
arction between nifedipine and placebo. New overt heart
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oi:10.1016/j.amjmed.2005.06.033ailure was better reduced with nifedipine than with pla-
ebo.
The authors of the ACTION study5 are to be commended
or thorough patient follow-up: Of the intended follow-up of
8 919 patient years, 97.3% were completed. Nifedipine
aused a significant decrease in blood pressure throughout
he ACTION study, which amounted to 6/2 mm Hg. Despite
his, there was no reduction in the primary or secondary end
oint (with the exception of new overt congestive heart
ailure). On the basis of the decrease in systolic pressure,
ne can calculate the predicted versus observed odds ratio
ccording to a metaregression model9 (Table 1). For
CTION, the difference between predicted versus observed
dds ratio was significant for cardiovascular events and
yocardial infarction. In the much smaller PREVENT10
nd NICOLE11,12 trials, similar to ACTION, patients with
oronary artery disease (n  825 and 826, respectively)
ere randomized to a calcium antagonist or placebo. The
utcome results of PREVENT and NICOLE were almost
dentical to those of ACTION. Indeed, amlodipine and ni-
oldipine when compared with placebo failed to reduce the
ncidence of myocardial infarction (Table 1), although these
rugs did decrease the risk of cardiovascular events, includ-
ng unstable angina, congestive heart failure, stroke, and
evascularization procedures. The recent CAMELOT13
tudy comparing amlodipine or enalapril versus placebo in
atients with coronary artery disease also showed very little
enefit. Similar to the other above studies, the primary
utcome results were mainly driven by coronary revascu-
arization and hospitalization for angina. This brings up the
uestion why blood pressure lowering with calcium antag-
nists did not reduce the risk of myocardial infarction in
atients with coronary artery disease, particularly in the
ufficiently powered ACTION trial?
u●
●
●
●
i
d
p
a
s
s
a
i
t
r
R
1419Messerli and Staessen ACTION and calcium antagonists safetyWe think there could be several different reasons for this
nexpected finding:
Although in the ACTION trial, concomitant medication
use was balanced at baseline, unequal use in the study
could explain some of these findings (ie, more beta-
blocker could have been used in the non-nifedipine arm).
An incremental reduction in cardiovascular events is diffi-
cult to achieve in patients with coronary artery disease who
are treated in a near-optimal way with antianginal, antihy-
pertensive, and lipid-lowering therapy. Beta-blocker use was
80% in ACTION and 76% in CAMELOT compared with
52% in EUROPA14 and 39% in HOPE.15 The respective
numbers for the use of lipid-lowering drugs were 68%, 83%,
57%, and 28%.
For any given decrease in systolic pressure, calcium an-
tagonists might be less effective in reducing the incidence
of coronary artery disease than other drug classes, such as
ACE inhibitors. Indeed, a recently completed meta-re-
gression analysis confirmed that decreasing blood pres-
sure is key to the prevention of cardiovascular complica-
tions, but it also showed small protective effects that were
not dependent on blood pressure, which differed for cal-
cium antagonists and ACE inhibitors with regard to
stroke and coronary heart disease (unpublished observa-
tions).
A decrease in diastolic pressure below a certain critical
level could increase the risk of myocardial infarction in
patients with coronary artery disease (J curve). Because
coronary arteries are perfused during diastole only, a J
curve, if any, should be most apparent for diastolic pres-
sure and coronary artery disease. Indeed, we recently
documented in the randomized INVEST study, with
22 000 patients, that the risk of primary outcome doubled
in patients with diastolic pressures less than 70 mm Hg
Table Predicted versus observed odds ratios for the ACTION, P
No. of events
(control/experimental) Pr
ACTION*
CV death 177/178 0.
CV events 536/507 0.
Stroke 99/77 0.
MI 257/267 0.
PREVENT*
CV death 2/7 0.
CV events 30/24 0.
Stroke 5/5 0.
MI 20/19 0.
NICOLE*
CV events 216/182 0.
Stroke 7/4 0.
MI 13/16 0.
CV  cardiovascular; MI  myocardial infarction.
*ACTION, PREVENT, and NICOLE are acronyms of double-placebo cont
nisoldipine in high-risk patients with preexisting coronary heart disease
mm Hg, respectively.and quadrupled in patients with diastolic pressures lessthan 60 mm Hg.16 No J curve was observed with systolic
pressure and the primary outcome or with diastolic pres-
sure and stroke. We concluded from the INVEST study
that the preponderance of myocardial infarction over
stroke at low diastolic pressure suggested that diastolic
hypotension could impair coronary perfusion and in-
crease the risk of coronary events in patients with coro-
nary artery disease.15
In conclusion, ACTION established the safety of nifed-
pine in patients with stable angina. However, despite the
ecrease in blood pressure, nifedipine did not reduce the
rimary outcome or risk of myocardial infarction. Conceiv-
bly, the detrimental effect of a decrease in diastolic pres-
ure could override the beneficial effect of a decrease in
ystolic pressure in this patient population with coronary
rtery disease (J curve). We therefore urge the ACTION
nvestigators to thoroughly analyze the shape of the rela-
ionship between on-treatment diastolic pressure and the
isk of coronary artery disease.
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